TARS stock forecast
Our latest prediction for Tarsus Pharmaceuticals Inc's stock price was made on the May 7, 2021 when the stock price was at 29.98$.
In the short term (2weeks), TARS's stock price should underperform the market by -2.65%. During that period the price should oscillate between -12.04% and +10.72%.
In the medium term (3months), TARS's stock price should underperform the market by -3.55%. During that period the price should oscillate between -38.34% and +32.03%.
Get email alertsCreate a solid portfolio with TARS
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.32$ per share.
The book value per share is 8.02$
Three months stock forecastMay 7, 2021
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -27M | - | -27M | -4.32 | - | - | 6M | 8.02 | -21M | - | -22M |